- Home
- MGNI vs VRDN Comparison
MGNI vs VRDN Comparison
Compare MGNI & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- VRDN
- Stock Information
- Founded
- MGNI 2007
- VRDN 2006
- Country
- MGNI United States
- VRDN United States
- Employees
- MGNI N/A
- VRDN N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- VRDN Medical Specialities
- Sector
- MGNI Technology
- VRDN Health Care
- Exchange
- MGNI Nasdaq
- VRDN Nasdaq
- Market Cap
- MGNI 1.4B
- VRDN 1.6B
- IPO Year
- MGNI N/A
- VRDN N/A
- Fundamental
- Price
- MGNI $15.10
- VRDN $12.39
- Analyst Decision
- MGNI Strong Buy
- VRDN Buy
- Analyst Count
- MGNI 14
- VRDN 14
- Target Price
- MGNI $18.64
- VRDN $36.82
- AVG Volume (30 Days)
- MGNI 2.8M
- VRDN 887.1K
- Earning Date
- MGNI 05-07-2025
- VRDN 05-06-2025
- Dividend Yield
- MGNI N/A
- VRDN N/A
- EPS Growth
- MGNI N/A
- VRDN N/A
- EPS
- MGNI 0.21
- VRDN N/A
- Revenue
- MGNI $674,622,000.00
- VRDN $302,000.00
- Revenue This Year
- MGNI $2.00
- VRDN N/A
- Revenue Next Year
- MGNI $10.95
- VRDN $20,553.29
- P/E Ratio
- MGNI $70.10
- VRDN N/A
- Revenue Growth
- MGNI 5.59
- VRDN 4.86
- 52 Week Low
- MGNI $8.22
- VRDN $9.90
- 52 Week High
- MGNI $21.29
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- MGNI 73.82
- VRDN 42.19
- Support Level
- MGNI $11.80
- VRDN $11.76
- Resistance Level
- MGNI $12.53
- VRDN $13.63
- Average True Range (ATR)
- MGNI 0.63
- VRDN 0.75
- MACD
- MGNI 0.44
- VRDN -0.02
- Stochastic Oscillator
- MGNI 77.82
- VRDN 22.11
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.